Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRH-882260 Heptapeptide for detection of colonic neoplasia
NCT03148119Phase 1Terminated
- Sponsor
- Danielle Kim Turgeon
- Start
- Mar 2017
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QRH-882260 in colorectal cancer (CRC), Colonic adenoma and dysplasia, sponsored by Danielle Kim Turgeon. Primary endpoint: Incidence of QRH-882260 Heptapeptide administration-related adverse events at 1 year. Started Mar 2017; status: terminated.
02
Drugs
QRH-882260
03
Conditions
colorectal cancer (CRC)Colonic adenomadysplasia
Beyond the preview
Go deeper on NCT03148119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148119.